ECSP055788A - Sistema de suministro de fármacos - Google Patents

Sistema de suministro de fármacos

Info

Publication number
ECSP055788A
ECSP055788A EC2005005788A ECSP055788A ECSP055788A EC SP055788 A ECSP055788 A EC SP055788A EC 2005005788 A EC2005005788 A EC 2005005788A EC SP055788 A ECSP055788 A EC SP055788A EC SP055788 A ECSP055788 A EC SP055788A
Authority
EC
Ecuador
Prior art keywords
treatment
supply system
medical device
drug supply
inflammatory
Prior art date
Application number
EC2005005788A
Other languages
English (en)
Inventor
Margaret Forney Prescott
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP055788A publication Critical patent/ECSP055788A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/22—Eight-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A61L2300/604—Biodegradation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Surgical Instruments (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

Un dispositivo o sistema de suministro de fármacos, el cual comprende: a) un dispositivo médico, por ejemplo un stent recubierto o un injerto de stent, adaptado para la aplicación o administración local en tubos huecos; y en conjunto con el mismo, b) una dosificación terapéutica de un derivado de ascomicina anti-inflamatorio, tal como pimecrolimus, por ejemplo fijado al dispositivo médico, y el uso del mismo en la preparación de un medicamento para la prevención y el tratamiento de complicaciones inflamatorias en seguida de lesión vascular, y un método de tratamiento con lo mismo.
EC2005005788A 2002-11-15 2005-05-10 Sistema de suministro de fármacos ECSP055788A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42680902P 2002-11-15 2002-11-15

Publications (1)

Publication Number Publication Date
ECSP055788A true ECSP055788A (es) 2005-08-11

Family

ID=32326430

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005788A ECSP055788A (es) 2002-11-15 2005-05-10 Sistema de suministro de fármacos

Country Status (17)

Country Link
US (1) US20060035879A1 (es)
EP (1) EP1585738A2 (es)
JP (1) JP2006522007A (es)
KR (1) KR20050086648A (es)
CN (1) CN1714085A (es)
AU (1) AU2003283399B2 (es)
BR (1) BR0316279A (es)
CA (1) CA2511573A1 (es)
CO (1) CO5690530A2 (es)
EC (1) ECSP055788A (es)
MX (1) MXPA05005196A (es)
NO (1) NO20052898L (es)
NZ (1) NZ539850A (es)
PL (1) PL376169A1 (es)
RU (1) RU2005118750A (es)
WO (1) WO2004045578A2 (es)
ZA (1) ZA200503502B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
US7208011B2 (en) * 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
US7056338B2 (en) * 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
US7758636B2 (en) * 2002-09-20 2010-07-20 Innovational Holdings Llc Expandable medical device with openings for delivery of multiple beneficial agents
CA2505576A1 (en) * 2002-11-08 2004-05-27 Conor Medsystems, Inc. Expandable medical device and method for treating chronic total occlusions with local delivery of an angiogenic factor
EP1610823B1 (en) 2003-03-28 2011-09-28 Innovational Holdings, LLC Implantable medical device with continuous agent concentration gradient
US20040202692A1 (en) * 2003-03-28 2004-10-14 Conor Medsystems, Inc. Implantable medical device and method for in situ selective modulation of agent delivery
US20040254629A1 (en) * 2003-04-25 2004-12-16 Brian Fernandes Methods and apparatus for treatment of aneurysmal tissue
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
EP1663978B1 (en) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
US20050033417A1 (en) * 2003-07-31 2005-02-10 John Borges Coating for controlled release of a therapeutic agent
US20050100577A1 (en) * 2003-11-10 2005-05-12 Parker Theodore L. Expandable medical device with beneficial agent matrix formed by a multi solvent system
JP2006028085A (ja) * 2004-07-15 2006-02-02 Shinshu Univ 血中コレステロール濃度低下作用物質
JP5622351B2 (ja) * 2004-09-03 2014-11-12 クレアビリス・セラピューティクス・エスピーエー プロテアーゼ抵抗性ヒトおよび非ヒトＨＭＧＢ１Ｂｏｘ−Ａ変異体、ならびにそれらの治療／診断への使用
JP5107716B2 (ja) * 2004-11-05 2012-12-26 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 分子治療用生分解性リンカー
US20090148458A1 (en) * 2005-06-23 2009-06-11 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
US20080004695A1 (en) * 2006-06-28 2008-01-03 Abbott Cardiovascular Systems Inc. Everolimus/pimecrolimus-eluting implantable medical devices
WO2008091925A2 (en) * 2007-01-23 2008-07-31 Cook Incorporated Treatment of aortic dissection or aneurysm
US20090104240A1 (en) * 2007-10-19 2009-04-23 Abbott Cardiovascular Systems Inc. Dual Drug Formulations For Implantable Medical Devices For Treatment of Vascular Diseases
US8689439B2 (en) 2010-08-06 2014-04-08 Abbott Laboratories Method for forming a tube for use with a pump delivery system
US8377000B2 (en) 2010-10-01 2013-02-19 Abbott Laboratories Enteral feeding apparatus having a feeding set
US8377001B2 (en) 2010-10-01 2013-02-19 Abbott Laboratories Feeding set for a peristaltic pump system
EP3634309B1 (en) * 2017-06-07 2023-05-24 Shifamed Holdings, LLC Adjustable optical power intraocular lenses
KR102136627B1 (ko) 2018-07-09 2020-07-22 세종대학교산학협력단 리포좀을 포함하는 염증성 장질환 예방, 개선 또는 치료용 약학 조성물 및 건강기능식품

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786216A (en) * 1987-11-17 1998-07-28 Cytotherapeutics, Inc. Inner-supported, biocompatible cell capsules
US5352671A (en) * 1989-11-09 1994-10-04 Sandoz Ltd. Heteroatoms-containing tricyclic compounds
DK0427680T3 (da) * 1989-11-09 1995-12-18 Sandoz Ltd Heteroatom-holdige cykliske forbindelser
WO1992015286A1 (en) * 1991-02-27 1992-09-17 Nova Pharmaceutical Corporation Anti-infective and anti-inflammatory releasing systems for medical devices
WO1993000063A1 (en) * 1991-06-28 1993-01-07 Brown University Research Foundation Capsule extrusion systems
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
US5843172A (en) * 1997-04-15 1998-12-01 Advanced Cardiovascular Systems, Inc. Porous medicated stent
US6153252A (en) * 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
US6713119B2 (en) * 1999-09-03 2004-03-30 Advanced Cardiovascular Systems, Inc. Biocompatible coating for a prosthesis and a method of forming the same
JP4754714B2 (ja) * 2000-06-01 2011-08-24 テルモ株式会社 管腔内留置物
AU1129902A (en) * 2000-09-29 2002-04-08 Cordis Corp Coated medical devices
US7018405B2 (en) * 2000-12-22 2006-03-28 Avantec Vascular Corporation Intravascular delivery of methylprednisolone
US20030033007A1 (en) * 2000-12-22 2003-02-13 Avantec Vascular Corporation Methods and devices for delivery of therapeutic capable agents with variable release profile
US20020082678A1 (en) * 2000-12-22 2002-06-27 Motasim Sirhan Intravascular delivery of mizoribine
US20020082679A1 (en) * 2000-12-22 2002-06-27 Avantec Vascular Corporation Delivery or therapeutic capable agents
US6471980B2 (en) * 2000-12-22 2002-10-29 Avantec Vascular Corporation Intravascular delivery of mycophenolic acid
US6939375B2 (en) * 2000-12-22 2005-09-06 Avantac Vascular Corporation Apparatus and methods for controlled substance delivery from implanted prostheses
EP1372753B1 (de) * 2001-02-16 2007-08-01 Abbott Laboratories Vascular Enterprises Limited Implantate mit fk506 zur restenosebehandlung und -prophylaxe
JP2002239013A (ja) * 2001-02-21 2002-08-27 Terumo Corp ステント及びその製造方法
BR0209474A (pt) * 2001-05-09 2006-02-07 Novartis Ag Métodos para imunomodulação seletiva
EP1273314A1 (en) * 2001-07-06 2003-01-08 Terumo Kabushiki Kaisha Stent
EP1501565B1 (de) * 2002-05-09 2006-11-02 Hemoteq GmbH Verbindungen und verfahren zur hemokompatiblen beschichtung von oberflächen

Also Published As

Publication number Publication date
NZ539850A (en) 2008-05-30
PL376169A1 (en) 2005-12-27
JP2006522007A (ja) 2006-09-28
ZA200503502B (en) 2006-07-26
WO2004045578A2 (en) 2004-06-03
AU2003283399A1 (en) 2004-06-15
NO20052898L (no) 2005-06-14
EP1585738A2 (en) 2005-10-19
CO5690530A2 (es) 2006-10-31
KR20050086648A (ko) 2005-08-30
CN1714085A (zh) 2005-12-28
RU2005118750A (ru) 2006-03-20
MXPA05005196A (es) 2005-07-22
US20060035879A1 (en) 2006-02-16
WO2004045578A3 (en) 2004-07-08
BR0316279A (pt) 2005-10-11
AU2003283399B2 (en) 2007-04-19
CA2511573A1 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
ECSP055788A (es) Sistema de suministro de fármacos
CY1113253T1 (el) Δοσολογικο σχημα για τη θεραπευτικη αντιμετωπιση μιας τραυματικης εγκεφαλικης βλαβης με προγεστερονη
CL2021001810A1 (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
CO5601015A2 (es) Sistema de administracion de farmacos que comprenden rapamicina y derivados de la misma para la prevencion y tratamiento de enfermedades vasculares
WO2008063319A3 (en) Methods of administering rapamycin analogs with anti-inflammatories using medical devices
WO2007047473A3 (en) Methods of administering rapamycin analogs with anti-inflammatories using medical devices
AR036458A1 (es) Dispositivos medicos que contienen analogos de rapamicina
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
PE20180203A1 (es) Procedimiento para la preparacion de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificacion para su uso como principio activo farmaceutico
WO2003082188A3 (en) Methods and drug delivery systems for the treatment of orofacial diseases
UY30321A1 (es) Procedimiento para preparar medicamentos caracterizado por el uso de derivados sustituidos de la 3-metil-7-(2-butin-1-il) xantina y aplicaciones
DK1576970T3 (da) Intraluminal indretning med en coating, der indeholder et terapeutisk middel
AR039985A1 (es) Compuesto de pirimidinona, composicion farmaceutica que lo comprende y su uso para la elaboracion de esta ultima
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
AR075846A1 (es) Sistema de administracion de farmaco de lactona macrociclica.uso. metodo de tratamiento
CU20090007A6 (es) Un compuesto farmacéutico y un proceso del mismo
WO2004043378A3 (en) Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
AR045783A1 (es) Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide
AR008886A1 (es) Uso de un inhibidor h+,k+-atpasa en la fabricacion de un medicamento para el tratamiento de polipos nasales, del sindrome de widal, uso de dicho inhibidor y un glucocorticoide para la fabricacion de una formulacion farmaceutica y formulacion farmaceutica para administracion simultanea
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
PE20130782A1 (es) Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
MX2010005009A (es) Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales.
AR037543A1 (es) Metodo para la terapia del cancer y composicion farmaceutica
AR022348A1 (es) Una composicion farmaceutica para el tratamiento de los sintomas del tracto urinario inferior